The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TIL | -51.81% | N/A | N/A | -98% |
| S&P | +13.19% | +87.83% | +13.42% | +72% |
Instil Bio, Inc. is a clinical-stage biopharmaceutical company engaged in developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company was founded in August 2018 and is headquartered in Dallas, TX.
A candidate that Instil Bio in-licensed this August is similar to a candidate that recently outperformed the world's top-selling cancer therapy.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.01M | 98.7% |
| Market Cap | $120.57M | -72.5% |
| Market Cap / Employee | $8.61M | 0.0% |
| Employees | 14 | -71.4% |
| Net Income | -$13.59M | 41.0% |
| EBITDA | -$15.01M | -44.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $6.08M | -8.7% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $84.61M | 1.2% |
| Short Term Debt | $0.31M | -82.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -31.00% | -6.5% |
| Return On Invested Capital | -34.24% | 10.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$10.56M | 47.6% |
| Operating Free Cash Flow | -$10.56M | 47.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.71 | 0.67 | 0.94 | 0.92 | -59.21% |
| Price to Tangible Book Value | 0.71 | 0.67 | 0.94 | 0.92 | -59.21% |
| Enterprise Value to EBITDA | -8.98 | -6.83 | -10.11 | -8.37 | -78.46% |
| Return on Equity | -37.5% | -44.5% | -51.7% | -50.6% | 38.12% |
| Total Debt | $86.89M | $86.67M | $84.88M | $84.92M | -0.50% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
